Bluebird Bio downgraded to Neutral from Overweight at JPMorgan
PremiumThe FlyBluebird Bio downgraded to Neutral from Overweight at JPMorgan
1M ago
Bluebird Bio reports Q2 revenue $16.1M vs .$6.9M last year
Premium
The Fly
Bluebird Bio reports Q2 revenue $16.1M vs .$6.9M last year
1M ago
Bluebird Bio sees recognizing revenue from LYFGENIA infusion  in Q3 or Q4
Premium
The Fly
Bluebird Bio sees recognizing revenue from LYFGENIA infusion in Q3 or Q4
1M ago
JPMorgan biotech analysts hold an analyst/industry conference call
PremiumThe FlyJPMorgan biotech analysts hold an analyst/industry conference call
3M ago
Bluebird Bio Announces CFO Transition and Compensation Details
Premium
Company Announcements
Bluebird Bio Announces CFO Transition and Compensation Details
4M ago
Bluebird Bio appoints James Sterling CFO succeeding Chris Krawtschuk
Premium
The Fly
Bluebird Bio appoints James Sterling CFO succeeding Chris Krawtschuk
4M ago
Class Action Lawsuit against Bluebird Bio, Inc. (NASDAQ:BLUE)
PremiumMarket NewsClass Action Lawsuit against Bluebird Bio, Inc. (NASDAQ:BLUE)
5M ago
Bluebird Bio completes commercial cell collection for LYFGENIA
Premium
The Fly
Bluebird Bio completes commercial cell collection for LYFGENIA
5M ago
Bluebird Bio Faces Nasdaq Compliance Challenge and Delays
Premium
Company Announcements
Bluebird Bio Faces Nasdaq Compliance Challenge and Delays
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100